226 results about "Subcutaneous injection" patented technology

The invention discloses a tree shrew depression model modeling method which comprises the following steps: (1) dissolving 20 mg of corticosterone in 10 microliters of DMSO (dimethylsulfoxide), and fixing the volume to 1 ml by normal saline; the method comprises the following steps: dissolving 100 mg of estradiol in 1 ml of DMSO (Dimethylsulfoxide) to prepare 100 mg / ml of estradiol stock solution; and (2) carrying out subcutaneous injection on the corticosterone solution prepared in the step (1) to tree shrews at 14: 00-16: 00 in the afternoon every day at the injection amount of 27 mu g / kg, diluting the estradiol stock solution prepared in the step (1) with normal saline after the corticosterone solution is injected for 1 hour, then carrying out subcutaneous injection on the tree shrews at the injection amount of 50-75 mu g / kg, and continuously injecting for 21 days to complete molding. According to the invention, a method of increasing the use dosage of corticosterone and simultaneously adding estradiol (estrogen with the highest in-vivo content and strongest activity) is adopted, so that the modeling time can be shortened. The corticosterone and the estradiol are combined for tree shrew depression modeling, so that the modeling time can be effectively shortened, and the optimal modeling effect is achieved by adopting a special estradiol dosage.

The present disclosure provides storage stable solid compositions including a biopharmaceutical agent and a polyacrylamide-based copolymer. The inventors have demonstrated that particular polyacrylamide-based copolymers can be used as stabilizing excipients in lyophilized formulations of biopharmaceutical agents. Also provided are methods of reconstituting and using the compositions, including methods of administering the reconstituted composition to a human subject in need thereof via injection, e.g., subcutaneous injection.

The present invention relates to a pharmaceutical composition comprising (a) a drug and (b) a human PH20 variant. The human PH20 variant included in the pharmaceutical composition according to the present invention comprises an alpha helix 8 sequence (S347-C381) selected from the wild-type human pH20 with the amino acid sequence SEQ ID NO:1 and an amino acid substitution at one or more positions of the connecting region (A333-R346) between alpha helix 7 and alpha helix 8, and is optionally cut at an amino acid located in the N-terminal or C-terminal region. In addition, the pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable additive, particularly a stabilizer. Due to the advantages of human PH20 variants, the pharmaceutical composition according to the present invention can show the maximum therapeutic effect of the drug used therewith.

The invention discloses an aprepitant nano suspension pharmaceutical composition and a preparation method thereof. The aprepitant nano suspension pharmaceutical composition comprises aprepitant, a space stabilizer, an electrostatic stabilizer and water, the steric stabilizer is selected from one or more of poloxamer F188, poloxamer F407 and polyvinylpyrrolidone K30, and the steric stabilizer is selected from one or more of poloxamer F188, poloxamer F407 and polyvinylpyrrolidone K30; the electrostatic stabilizer is lauryl sodium sulfate or PCM. By selecting a specific stabilizer and a preparation method, subcutaneous injection of aprepitant is realized, the stability of the medicine is remarkably improved, and the medicine loading capacity is increased. In addition, according to the method, the preparation process is simplified, the formula screening time is shortened, and therefore the overall preparation time is shortened.

The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.

The invention discloses a preparation method of a self-crosslinking hyaluronic acid microsphere without an exogenous crosslinking agent, which comprises the following steps: activating carboxyl on hyaluronic acid only by using an activator with good biocompatibility, carrying out esterification reaction on the activated carboxyl and hydroxyl on the hyaluronic acid, and curing and crosslinking water-in-oil emulsion at room temperature by continuously stirring to obtain the self-crosslinking hyaluronic acid microsphere without the exogenous crosslinking agent. The self-crosslinking hyaluronic acid microspheres are formed. As an exogenous cross-linking agent is not introduced, hyaluronic acid forms an ester bond through self-crosslinking after being activated instead of forming an amido bond with the exogenous cross-linking agent, and the formation of the ester bond can effectively improve the storage modulus of the hyaluronic acid microspheres. Compared with a commercially available sieved gel product, the self-crosslinked hyaluronic acid microsphere disclosed by the invention has the advantages that the crosslinking degree is higher, the immunogenicity risk of free HA is reduced, the self-crosslinked hyaluronic acid microsphere is suitable for deep or subcutaneous injection of dermis, and a more uniform three-dimensional support is provided.

The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home-use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.

To provide a highly concentrated liquid antibody formulation that is storage stable and suitable for subcutaneous administration.SOLUTION: The present disclosure inter alia provides a liquid pharmaceutical formulation comprising a) 150 mg / ml of an anti-IL-23p19 antibody, the antibody comprising a specific light chain amino acid sequence and a specific heavy chain amino acid sequence; b) a polyol; and c) a surfactant.SELECTED DRAWING: None

The invention discloses a method for establishing a cat osteoarthritis pain model, which comprises the following steps of: performing experimental research on immunogen, drug concentration, immunization frequency, administration route, injection dosage and the like, and adopting collagen immunogen and 1% carrageenan immunogen as mixed immunogen; a cat is immunized by adopting a two-point injection mode of subcutaneous injection near a shoulder blade and plantar subcutaneous injection, the immunization procedure adopts twice immunization of 0 day and 7 days, a simple and efficient cat osteoarthritis pain model is successfully constructed, the model has obvious joint and claw swelling, a cat claw retraction threshold value is reduced, a TNF-a factor is obviously increased, and the model can be used for researching the pain of the cat osteoarthritis, the pain of the cat osteoarthritis and the pain of the cat osteoarthritis. The method can be used for researching the pathogenesis, pathological change, pain mechanism and OA treatment method of the cat osteoarthritis, and can also be used for evaluating the clinical effect of a novel analgesic drug for the cat osteoarthritis.

The invention relates to the technical field related to biological medicine, and particularly provides an anti-bovine rotavirus recombinant protein vaccine composition and application thereof. The recombinant protein vaccine composition for resisting bovine rotavirus comprises a first recombinant protein vaccine which is administrated through nasal drop and a second recombinant protein vaccine which is administrated through subcutaneous injection, the first recombinant protein vaccine comprises VP6 recombinant protein and LTB recombinant protein; the second recombinant protein vaccine comprises VP7 recombinant protein. According to the recombinant protein vaccine disclosed by the invention, the combination of the first recombinant protein vaccine which is administrated through nasal dripping and the second recombinant protein vaccine which is administrated through subcutaneous injection is used, so that the comprehensiveness of preventing the bovine rotavirus is improved.

Most therapeutic treatments require dose adjustment after initial administration. Dosage adjustment is crucial to ensuring optimal safety and efficacy characteristics of the treatment. Gene therapy is inherently limited by the inability to adjust the dose after initial administration. This invention describes a genetic element capable of dose adjustment after the initial administration of gene therapy. The realization of dose adjustment allows for the replacement of multiple subcutaneous protein injection regimens with single-injection gene therapy, thereby improving pharmacokinetics, safety / efficacy characteristics, medication adherence, and reducing healthcare costs.

The present invention relates to a pharmaceutical composition comprising (a) a drug and (b) a human PH20 variant. The human PH20 variant comprised in the pharmaceutical composition according to the present invention comprises amino acid substitutions at one or more positions selected from the alpha helix 8 sequence (S347-C381) and a linking region (A333-R346) between alpha helix 7 and alpha helix 8 on wild-type human pH20 having the amino acid sequence SEQ ID NO: 1, and optionally cleaved at the amino acid located at the N-terminal or C-terminal region. In addition, the pharmaceutical composition according to the present invention may further comprise a pharmaceutically acceptable additive, in particular a stabilizer. Due to the advantages of the human PH20 variant, the pharmaceutical composition according to the present invention can exhibit a maximum therapeutic effect of a drug used therewith.

The present invention relates to aqueous compositions comprising dantrolene and optionally also at least one additional active principle, such as botulinum neurotoxin, and their use for various therapeutic and / or aesthetic / cosmetic purposes. The compositions can be administered in any suitable way but are advantageous in that they are particularly well adapted to intramuscular injection, subcutaneous injection and / or intradermal injection.

A pharmaceutical combination for subcutaneous administration and use thereof are provided. The pharmaceutical combination as described herein for subcutaneous administration includes a hyaluronidase and an antibody-drug conjugate. The antibody-drug conjugate includes a fragment of a bioactive molecule, and the bioactive molecule has moderate toxicity. The pharmaceutical combination can achieve a larger volume and a larger dose of administration, and the side reaction is not enhanced.

The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or without hyaluronidase every six weeks, in specific amounts to the patient. In specific embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 600 mg to about 1000 mg. In specific embodiments, the administration occurs about every three weeks, and the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 300 mg to about 500 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a particular dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

The present invention discloses a preparation method of injectable sodium hyaluronate-coated polylactic acid microspheres. The sodium hyaluronate-coated polylactic acid microspheres are prepared by the emulsion method. On the one hand, by utilizing the good hydrophilic property of hyaluronic acid itself, the freeze-dried sodium hyaluronate-coated polylactic acid microspheres can be well redissolved in injection water, greatly reducing problems such as long redissolution time and uneven particle dispersion. On the other hand, after the sodium hyaluronate-coated polylactic acid microspheres are subcutaneously injected, the first thing they contact is sodium hyaluronate with better biocompatibility, avoiding the more irritating inflammatory phenomenon caused by direct contact with the polylactic acid microspheres. As the sodium hyaluronate on the outer layer of the microspheres is enzymatically degraded, the inner layer of polylactic acid microspheres will be exposed, further playing a role in stimulating the body's own collagen production. In addition, the preparation method of the present invention has simple technological steps and is suitable for large-scale preparation for industrial applications.

The present disclosure provides methods for treating thyroid eye disease, comprising subcutaneously administering a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment to a patient in need of treatment. Also provided herein are pharmacologically active agents, compositions, methods, and / or administration schedules for the treatment of thyroid eye disease.

This invention belongs to the field of vertebrate technology, specifically relating to a method for constructing a complex inflammatory animal model in middle-aged and elderly individuals and its related applications. The method includes: selecting adult animals for adaptive feeding, daily subcutaneous injection of D-galactose to establish a susceptibility to aging and oxidative stress, and administering sodium dextran sulfate (DSS) solution within a specific time window to induce intestinal inflammation, forming a complex inflammatory state through gut-hepatic axis interactions. The constructed animal model simultaneously exhibits intestinal inflammatory damage, abnormal hepatic oxidative stress, and aging-related characteristics, realistically simulating the pathological process of gut-hepatic axis dysfunction in middle-aged and elderly individuals. This model is suitable for screening and evaluating drugs, medical nutrition products, and functional foods that improve gut-hepatic axis dysfunction, providing a reliable technical platform for research on related disease mechanisms and the development of interventional substances.

The present invention relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition comprising the same for subcutaneous administration, and a method for preparing the same. In the case of using the preparation method of the present invention, nanoparticles comprising sirolimus and albumin having excellent stability of particle size distribution can be prepared, the prepared nanoparticles can be prepared as a pharmaceutical composition suitable for subcutaneous injection, and the increase in administration dose and the convenience of administration can be improved.

The invention relates to a device (100), particularly a cosmetic one, for the subcutaneous injection of gas, in particular carbon dioxide (CO2), comprising a gas reservoir (10) in fluidic communication with a hollow microneedle (4) having an internal channel of mean internal transverse dimension (IDmoy), the hollow injection microneedle (4) having a length (L) less than or equal to 250 mm and greater than or equal to 70 mm. [Fig. 1]

The present invention provides an injectable depot composition comprising enavogliflozin and a low-dose liraglutide. A combination regimen of enavogliflozin and a low-dose liraglutide provides a synergistic effect in the treatment of obesity compared to the sole administration of either of the drugs. In addition, compared to the sole administration of liraglutide, the administered dose of liraglutide can be reduced, and thus direct causes of gastrointestinal and cardiovascular side effects of liraglutide can be mitigated. In addition, the present invention has the advantage of additionally providing the effect of alleviating metabolic diseases and cardiovascular diseases related to blood glucose, blood lipids, blood pressure, fatty liver, and the like through combined administration with enavogliflozin. Furthermore, the depot composition of enavogliflozin and liraglutide according to the present invention can significantly improve medication convenience and medication adherence for a patient compared to existing liraglutide formulations, which are subcutaneously injected once a day, by unifying the route of administration and improving the administration cycle.

The invention relates to the technical field of medical instruments, in particular to an application type ultrathin subcutaneous injection device which comprises a storage layer, a storage groove used for storing liquid medicine is formed in the top of the storage layer, and a filling assembly used for supplementing the liquid medicine is arranged at the top of the storage layer; a driving layer is fixedly connected to the bottom of the storage layer, a liquid inlet cavity and a liquid outlet cavity are formed in the top of the driving layer, a liquid outlet is formed in the storage groove and communicates with the liquid inlet cavity, and the communicating position of the liquid outlet and the liquid inlet cavity communicates with a first one-way valve for feeding liquid into the liquid inlet cavity; the liquid inlet cavity is communicated with the liquid discharging cavity, and a second one-way valve for discharging liquid from the liquid inlet cavity is communicated with the communicating part of the liquid inlet cavity and the liquid discharging cavity; the bottom of the driving layer is fixedly connected with an injection layer; an injection cavity is formed in the top of the injection layer and is communicated with the liquid discharge cavity; through the design of the storage layer, the driving layer and the injection layer, the size of the device can be effectively reduced, the body burden of a patient is effectively relieved, and the convenience of the device and the comfort of the patient are improved.

This utility model discloses a portable syringe plunger auxiliary device, comprising: a base and a power supply module. A syringe holder and an electric plunger are mounted on the base; the syringe holder is configured to engage an injection syringe; the electric plunger is positioned such that its output shaft extends toward the syringe holder, and the electric plunger pushes the piston handle of the injection syringe engaged in the syringe holder toward the needle tip of the injection syringe; the power supply module is installed within the base and electrically connected to the electric plunger through a first power supply circuit, and the power supply module supplies power to the electric plunger. This utility model helps nursing personnel achieve a stable and uniform injection operation over a long period during subcutaneous injections.

1. The name of the design product: insulin injection simulation artificial skin. 2. The use of the design product: the product is mainly used to demonstrate injection site selection and injection process in subcutaneous injection education process. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best indicates the design points: perspective view. 5. The design for which protection is sought contains color. 6. The back of the design product is a part that is not easy to see or cannot be seen during use, and the rear view is omitted.

The invention discloses a method for preparing silk fibroin and hyaluronic acid composite gel, which comprises the following steps of: uniformly mixing hyaluronate with a first solvent to prepare hyaluronic acid gel, mixing the hyaluronic acid gel with a silk fibroin solution, shearing at a high speed, homogenizing and emulsifying, standing, shearing at a high speed, homogenizing and emulsifying, sealing and sterilizing to obtain the silk fibroin and hyaluronic acid composite gel. According to the method disclosed by the invention, reagents such as a cross-linking agent, an initiator and enzyme do not need to be additionally added; the silk fibroin solution and the hyaluronic acid gel can form uniform and mutually-crosslinked double networks in the homogeneous gel forming process, the phase separation risk is low, and the silk fibroin can generate an emulsion reaction through high-speed homogenization, so that the color of the composite gel is whiter; the preparation method disclosed by the invention is simple, rapid in emulsification and gel forming, short in production cycle, low in endotoxin of the product, high in biocompatibility, slow in degradation, small in inflammatory response and high in injection filling safety, and the composite gel can play a role in moisturizing and moisturizing after subcutaneous injection and has the whitening effects of improving skin elasticity and glossiness, fading fine wrinkles and the like.

The invention discloses near-infrared thermal molecules, nano particles, injectable near-infrared thermal hydrogel and application of the injectable near-infrared thermal hydrogel in preparation of anti-obesity drugs. The structural formula of the near-infrared photothermal molecule is shown in the specification. According to the invention, molecular structure design is carried out to obtain near-infrared thermal molecules with strong near-infrared absorption, bright near-infrared two-region fluorescence emission and high photo-thermal stability; near-infrared photothermal molecules are packaged into spherical nanoparticles by using an amphiphilic polymer through a nanoprecipitation method, the spherical nanoparticles are further mixed with a temperature-sensitive matrix material to prepare the near-infrared photothermal hydrogel capable of being subcutaneously injected, after near-infrared irradiation, adipocyte apoptosis can be remarkably induced, meanwhile, white fat is promoted to be converted into beige fat, and the effect of preparing the near-infrared photothermal hydrogel is achieved. The efficient anti-obesity effect is achieved; and hydrogel degradation, medicament distribution and treatment processes can be tracked in real time through near-infrared two-region fluorescence imaging, so that the controllability and accuracy of treatment are improved. The whole system shows good biocompatibility, and has outstanding application potential in the anti-obesity field.

The invention discloses a comprehensive automatic immunization all-in-one machine which comprises a machine base, and a controller, a poultry intramuscular injection device, a poultry neck posterior subcutaneous injection device, a poultry wing membrane stabbing device and a poultry eye drop immunization device which are arranged on the machine base, the poultry intramuscular injection device, the poultry posterior-neck subcutaneous injection device, the poultry eye drop immunization device and the poultry wing membrane stabbing device are controlled by the controller, the poultry intramuscular injection device is used for performing intramuscular injection on poultry, and the poultry posterior-neck subcutaneous injection device is used for performing posterior-neck subcutaneous injection on poultry; the poultry eye dropping immunization device is used for carrying out eye dropping operation on poultry, and the poultry wing membrane stabbing device is used for carrying out stabbing injection on wing membranes of the poultry. The situation that traditional artificial immunization is high in labor intensity and low in efficiency is changed, the work efficiency of immunization inoculation is greatly improved, and meanwhile the equipment purchase cost and the site occupied area are reduced; moreover, the poultry grabbing frequency is reduced, the irritability is reduced, and the timeliness and continuity of immunization are improved.

The present invention relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition for subcutaneous administration, comprising same, and a preparation method therefor. If the preparation method of the present invention is used, nanoparticles comprising sirolimus and albumin and having excellent improved particle size distribution maintenance stability can be prepared, and the prepared nanoparticles can be prepared in a pharmaceutical composition suitable for subcutaneous injection, and thus dosage is increased and convenience of administration is improved.

Provided herein are ketamine formulations for subcutaneous injection, in particular subcutaneous formulations of ketamine useful for the treatment of various diseases and disorders. The subcutaneous ketamine preparation provided by the invention reduces stimulation and pain of an injection site.

A stable pharmaceutical formulation according to the present invention comprises: (A) Ixekizumab; and (B) a histidine buffer. A stable pharmaceutical formulation according to the present invention comprises an antibody, has excellent long-term storage stability on the basis of having excellent stability especially under accelerated conditions and severe conditions, and can be administered intravenously or subcutaneously.